Compare ProShares Ultra QQQ ETF (QLD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Zimmer Biomet Holdings Inc — how do they compare? ProShares Ultra QQQ ETF trades at $88.3, while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Zimmer Biomet Holdings Inc pays a 1.08% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| QLD | ZBH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $107.71 |
52-Week Low | $57.16 | $79.58 |
Market Cap | — | $17.20B |
Enterprise Value | — | $24.25B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD, the ProShares Ultra QQQ ETF, trades at $86.06, up 0.17% on the day, with a bearish technical signal driven by moving averages. The ETF, which provides 2x daily leveraged exposure to the Nasdaq-100 index, has delivered over 10,000% total return since inception, demonstrating powerful long-term compounding. Recent news highlights its role in tech-focused strategies amid a Nasdaq comeback, though leveraged structure amplifies volatility.
Outlook is mixed: technicals suggest near-term caution, but long-term growth potential remains tied to tech sector performance. Key risks include daily rebalancing effects in volatile markets and significant drawdowns, as seen historically. Investors should weigh leveraged benefits against inherent volatility and holding period considerations.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
